Pronethalol decreases RBPJκ to reduce Sox2 in cerebral arteriovenous malformation

Vasc Med. 2020 Dec;25(6):569-571. doi: 10.1177/1358863X20942833. Epub 2020 Aug 24.
No abstract available

Keywords: beta-adrenergic antagonist; cerebral arteriovenous malformations.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-Antagonists / pharmacology*
  • Binding Sites
  • Brain / blood supply*
  • Cells, Cultured
  • Down-Regulation
  • Endothelial Cells / metabolism
  • Endothelial Cells / pathology*
  • Ethanolamines / pharmacology*
  • Humans
  • Immunoglobulin J Recombination Signal Sequence-Binding Protein / genetics
  • Immunoglobulin J Recombination Signal Sequence-Binding Protein / metabolism*
  • Intracranial Arteriovenous Malformations / drug therapy*
  • Intracranial Arteriovenous Malformations / genetics
  • Intracranial Arteriovenous Malformations / metabolism
  • Promoter Regions, Genetic
  • SOXB1 Transcription Factors / genetics
  • SOXB1 Transcription Factors / metabolism*
  • Signal Transduction

Substances

  • Adrenergic beta-Antagonists
  • Ethanolamines
  • Immunoglobulin J Recombination Signal Sequence-Binding Protein
  • RBPJ protein, human
  • SOX2 protein, human
  • SOXB1 Transcription Factors
  • pronethalol